Abstracts tagged "Patient reported outcomes"

Abstract Number: 1234 • ACR Convergence 2021
Routine Assessment of Patient Index Data 3 (RAPID3) in Patients with Rheumatoid Arthritis Treated with Long-Term Upadacitinib Therapy
Martin Bergman¹, Maya Buch², Yoshiya Tanaka³, Gustavo Citera⁴, Sami Bahlas⁵, Ernest Wong⁶, Yanna Song⁷, Namita Tundia⁷, Jessica Suboticki⁷ and Vibeke Strand⁸, ¹Martin Jan Bergman, MD, Ridley Park, PA, ²University of Leeds, Leeds, United Kingdom, ³University of Occupational and Environmental Health, Kitakyushu, Japan, ⁴Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, ⁵Medicine, King Abdulaziz University, Jeddah, Saudi Arabia, ⁶Rheumatology, Queen Alexandra Hospital, Portsmouth, United Kingdom, ⁷AbbVie Inc., North Chicago, IL, ⁸Stanford University School of Medicine, Portola Valley, CA
Background/Purpose: Routine Assessment of Patient Index Data 3 (RAPID3) is a pooled index of 3 patient-reported measures: patient global assessment, pain, and physical function. RAPID3…
Abstract Number: 1419 • ACR Convergence 2021
Development and Validation of a Patient Reported Outcome Measure for Giant Cell Arteritis
Mwidimi Ndosi¹, Celia Almeida², Jill Dawson³, Emma Dures², Rosemary Greenwood⁴, Catherine Guly⁵, Sarah Mackie⁶, Alison Bromhead⁴, Steve Stern⁴ and Joanna Robson², ¹University of the West of England, Bristol, Filton, United Kingdom, ²UWE Bristol, Bristol, United Kingdom, ³University of Oxford, Oxford, ⁴University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, United Kingdom, ⁵University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, ⁶School of Medicine, University of Leeds, Leeds, United Kingdom
Background/Purpose: Giant cell arteritis (GCA) causes inflammation of the blood vessels of the head and neck and can cause visual loss and large vessel vasculitis.…
Abstract Number: 1711 • ACR Convergence 2021
Increasing Preeclampsia Knowledge in SLE with a Specific Educational Tool: Preliminary Results
Joo Young (Esther) Lee¹, Arielle Mendel², Isabelle Malhamé², Sasha Bernatsky¹ and Evelyne Vinet³, ¹McGill University, Montréal, QC, Canada, ²McGill University Health Centre, Montréal, QC, Canada, ³McGill University Health Centre, Mont Royal, QC, Canada
Background/Purpose: Pregnant women with systemic lupus erythematosus (SLE) are at high risk of preeclampsia, leading to substantial maternal and fetal morbidity. Aspirin reduces preeclampsia risk…
Abstract Number: 0225 • ACR Convergence 2021
Prevalence of Sexual Dysfunction and Depression in German Patients with Psoriasis and Psoriatic Arthritis – Results of the PIPPA Study
Sebastian Saur¹, Alexandra Schloegl², Caroline Höppner³, Anastasia Gubar², Katharina Meier⁴, Matthias Hahn² and Jorg Henes², ¹Universtiy Hostpiatl Tübingen, Tuebingen, Germany, ²University Hospital Tuebingen, Tuebingen, Germany, ³Charite Berlin, Berlin, Germany, ⁴Department of Dermatology, Venereology and Allergology – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, Berlin, Germany
Background/Purpose: As known chronic inflammatory diseases have an impact on sexuality. To date, there are only a few studies from North and Latin America which…
Abstract Number: 0476 • ACR Convergence 2021
Factors Associated with Pain Reduction and Improved Well-Being Among Fibromyalgia Patients Using Medical Cannabis
Marc Martel¹, Lilach Eyal Waldman¹, Romina Sotoodeh¹, Antonio Vigano¹, Yola Moride², Michelle Canac-Marquis³, Rihab Gamaoun³, Maja Kalaba⁴, Pierre Beaulieu², Julie Desroches², Mark A. Ware⁴, Jordi Perez³, Yoram Shir³ and Mary-Ann Fitzcharles¹, ¹McGill University, Montréal, QC, Canada, ²Université de Montréal, Montréal, QC, Canada, ³McGill University Health Centre, Montréal, QC, Canada, ⁴Canopy Growth Corporation, Montréal, QC, Canada
Background/Purpose: Fibromyalgia (FM) is characterized by a constellation of symptoms that are often poorly responsive to current treatments, and patients are increasingly turning to medical…
Abstract Number: 0745 • ACR Convergence 2021
Patient-reported Outcomes and Safety Measures in Patients with Rheumatic Diseases Who Switched from Reference or Other Biosimilar Etanercept to Biosimilar Etanercept GP2015 and in Biologic-naïve Patients Starting a Treatment with GP2015: 12-month Interim Analysis from a Real-world Study
Ayman Askari¹, Marc Schmalzing², Slawomir Jeka³, Javier De Toro Santos⁴, Eduardo Collantes-Estevez⁵, Fabricio Furlan⁶, Sohaib Hachaichi⁶ and Herbert Kellner⁷, ¹The Robert Jones and Agnes Hunt Orthopaedic Hospital, Shropshire, United Kingdom, ²Rheumatology/Clinical Immunology, Department of Internal Medicine II, University of Wuerzburg, Wuerzburg, Germany, ³Clinic and Department of Rheumatology and Connective Tissue Diseases, University Hospital No 2 in Bydgoszcz Collegium Medicum UMK in Toruń, Bydgoszcz, Poland, ⁴University Hospital Coruña, Servicio de Reumatología, A Coruña, Galicia, Spain, ⁵IMIBIC/Reina Sofia Hospital/University of Córdoba, Córdoba, Spain, ⁶Hexal AG (A Sandoz company), Holzkirchen, Germany, Holzkirchen, Germany, ⁷Hospital Neuwittelsbach, Center for Rheumatology and Gastroenterology, Munich, Germany, Munich, Germany
Background/Purpose: GP2015 is a biosimilar of etanercept (ETN). COMPACT is an ongoing, non-interventional study, evaluating the effectiveness, safety, and quality of life with GP2015 treatment…
Abstract Number: 0773 • ACR Convergence 2021
Janus Kinase (JAK) Inhibition with Baricitinib: Dosing and Patient-Reported Outcomes in Refractory Juvenile Dermatomyositis
Hanna Kim¹, Ly-Lan Bergeron², Samantha Dill², MIchelle O'Brien², Xiaobai Li³, Jomy George³, April Brundidge², Michelle Millwood², Lisa Rider⁴ and Robert Colbert⁵, ¹Juvenile Myositis Pathogenesis and Therapeutics Unit, NIAMS, National Institutes of Health, Bethesda, MD, ²Office of Clinical Director, NIAMS, National Institutes of Health, Bethesda, MD, ³Clinical Center, National Institutes of Health, Bethesda, MD, ⁴NIEHS, NIH, Garrett Park, MD, ⁵NIH/NIAMS, Bethesda, MD
Background/Purpose: Juvenile dermatomyositis (JDM) is a systemic autoimmune disease with a prominent interferon (IFN) signature. Treatment often requires prolonged high-dose steroids and other immunosuppressive medications.…
Abstract Number: 1073 • ACR Convergence 2021
In Favor of the Subspecialty Clinic Model for Rheumatoid Arthritis
Jasmine Thai¹, Roshan Patel¹, Yeohan Song¹ and Sheryl Mascarenhas², ¹Ohio State University, Columbus, OH, ²Ohio State University Hospital, Columbus, OH
Background/Purpose: The Subspecialty Clinic Model (SCM) which seeks to allow for collaborative care and services by stratifying patients with a particular disease or need to…
Abstract Number: 1244 • ACR Convergence 2021
Mindfulness-Based Stress Reduction (MBSR) to Improve Patient-Related Outcomes (PROs) in Patients with Rheumatoid Arthritis in Clinical Remission but Elevated Negative PROs: A Pragmatic Pilot Study
Marie-Claude Beaulieu¹, Isabelle Gaboury², Patricia L Dobkin³, Nathalie Carrier⁴, France Gervais⁵, Françoise Gendron⁶, Pasquale Roberge⁷, PIERRE DAGENAIS⁷, Sophie Roux⁷ and Gilles Boire¹, ¹Universite de Sherbrooke, Sherbrooke, QC, Canada, ²University of Sherbrooke, Sherbrooke, QC, Canada, ³McGill University, Montréal, QC, Canada, ⁴CIUSSS de l'Estrie - CHUS, Sherbrooke, QC, Canada, ⁵NA, Rimouski, QC, Canada, ⁶NA, Sherbrooke, QC, Canada, ⁷Université de Sherbrooke, Sherbrooke, QC, Canada
Background/Purpose: Many patients with controlled rheumatoid arthritis (RA) continue to report high levels of disease activity (PGA), as well as other disturbing patient-related outcomes (PROs),…
Abstract Number: 1537 • ACR Convergence 2021
Impact of COVID-19 Infection on Patient-Reported Outcomes in Rheumatic Disease Patients: A Cross Sectional Study
Elaine Husni¹, Cassandra Calabrese², Brittany Lapin¹, Elizabeth Kirchner³ and Leonard Calabrese¹, ¹Cleveland Clinic, Cleveland, OH, ²Cleveland Clinic Foundation, Cleveland Heights, OH, ³CCF, Cleveland, OH
Background/Purpose: The persistence of symptoms following COVID 19 is an area of great interest yet remains poorly understood. Long COVID symptoms are dominated by fatigue…
Abstract Number: 1725 • ACR Convergence 2021
Higher Prevalence of Aspirin Use with a Specific Educational Tool in SLE Pregnancies: Preliminary Results
Joo Young (Esther) Lee¹, Arielle Mendel², Isabelle Malhamé², Sasha Bernatsky¹ and Evelyne Vinet³, ¹McGill University, Montréal, QC, Canada, ²McGill University Health Centre, Montréal, QC, Canada, ³McGill University Health Centre, Mont Royal, QC, Canada
Background/Purpose: Pregnant women with SLE are at substantial risk of preeclampsia. Best international practice guidelines recommend aspirin (ASA) in this population, as it reduces preeclampsia…
Abstract Number: 0231 • ACR Convergence 2021
Reducing the Number of Outpatient Clinic Visits by Using the Routine Assessment of Patient Index Data 3 as a Screening Tool
Jimmy Wiegel¹, Bart Seppen¹, Marieke ter wee², Maarten Boers³, Michael Nurmohamed⁴ and wouter Bos⁵, ¹Reade, Amsterdam, Netherlands, ²Amsterdam UMC, location VUmc, Amsterdam, Netherlands, ³Amsterdam UMC, Vrije Universiteit, Amsterdam, Netherlands, ⁴Reade and Amsterdam University Medical Center, location VUmc, Amsterdam, Netherlands, ⁵Reade Amsterdam, Amsterdam, Netherlands
Background/Purpose: The long-term and frequent evaluation of disease activity in patients with rheumatoid arthritis (RA) leads to a large burden of planned consultations at outpatient…
Abstract Number: 0481 • ACR Convergence 2021
The Day-to-day Variability of Pain and the Relationship with Physical Activity in People with Knee Osteoarthritis: A Longitudinal, Observational Feasibility Study
Arani Vivekanantham¹, David Selby², Mark Lunt², Terence O’Neill² and Will Dixon², ¹University of Oxford, Oxford, United Kingdom, ²University of Manchester, Manchester, United Kingdom
Background/Purpose: Pain is a cardinal symptom in people with knee osteoarthritis (OA). However, pain in knee OA is often infrequently measured both in clinical practice…
Abstract Number: 0746 • ACR Convergence 2021
Application of Existing Patient-Reported Outcome Measures for Telehealth Encounters: What’s Feasible?
Patricia Katz¹, Meera Subash¹, Martin Bergman² and Kaleb Michaud³, ¹University of California San Francisco, San Francisco, CA, ²Martin Jan Bergman, MD, Ridley Park, PA, ³University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Validated patient-reported outcome (PRO) measures play important roles in assessing and managing of patients with rheumatic diseases. However, use of these validated scales may…
Abstract Number: 0797 • ACR Convergence 2021
Psychosocial Wellbeing and Illness Perceptions During the Early Disease Phase Predict Sustained Remission in Rheumatoid Arthritis
Michal Doumen¹, Diederik De Cock¹, Sofia Pazmino¹, Delphine Bertrand¹, Rene Westhovens² and Patrick Verschueren³, ¹KU Leuven, Leuven, Belgium, ²University Hospitals KU Leuven, Maaseik, Belgium, ³University Hospitals Leuven - KULeuven, Leuven, Belgium
Background/Purpose: Patient-reported outcomes (PROs) relating to global psychosocial wellbeing are rarely assessed in clinical trials for rheumatoid arthritis (RA), and specifically not to tailor additional…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].